ABBV’s guidance for NDA/MAA submissions of 3-DAA GT1 regimen is now early 2Q14 (i.e. April); the prior guidance had been simply 2Q14. (Source: ABBV’s JPM webcast.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”